Rhumbline Advisers raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 284,745 shares of the life sciences company’s stock after buying an additional 6,950 shares during the period. Rhumbline Advisers’ holdings in Illumina were worth $62,214,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the business. Jennison Associates LLC boosted its position in shares of Illumina by 8.8% during the fourth quarter. Jennison Associates LLC now owns 4,412,621 shares of the life sciences company’s stock valued at $964,114,000 after buying an additional 355,200 shares during the period. Ameriprise Financial Inc. boosted its position in shares of Illumina by 3.1% during the third quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock valued at $500,416,000 after buying an additional 76,452 shares during the period. Legal & General Group Plc boosted its position in shares of Illumina by 2.6% during the third quarter. Legal & General Group Plc now owns 684,955 shares of the life sciences company’s stock valued at $136,442,000 after buying an additional 17,081 shares during the period. American Century Companies Inc. boosted its position in shares of Illumina by 5.6% during the fourth quarter. American Century Companies Inc. now owns 639,184 shares of the life sciences company’s stock valued at $139,655,000 after buying an additional 34,035 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Illumina by 6.4% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 541,063 shares of the life sciences company’s stock valued at $118,217,000 after buying an additional 32,695 shares during the period. Institutional investors and hedge funds own 92.04% of the company’s stock.
ILMN has been the subject of several recent analyst reports. Citigroup boosted their target price on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a research report on Wednesday, October 25th. Robert W. Baird upgraded Illumina from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $184.00 to $228.00 in a research report on Wednesday, October 25th. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. Barclays boosted their price target on Illumina from $200.00 to $215.00 and gave the company an “equal weight” rating in a report on Wednesday, January 31st. Finally, Cowen boosted their price target on Illumina from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Monday, January 22nd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the stock. Illumina has a consensus rating of “Buy” and an average price target of $241.39.
In related news, Director Jay T. Flatley sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $243.72, for a total value of $3,655,800.00. Following the completion of the transaction, the director now owns 449,201 shares of the company’s stock, valued at $109,479,267.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert S. Epstein sold 1,250 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $226.55, for a total transaction of $283,187.50. Following the completion of the transaction, the director now directly owns 9,088 shares of the company’s stock, valued at approximately $2,058,886.40. The disclosure for this sale can be found here. Insiders sold 114,440 shares of company stock valued at $25,318,904 in the last three months. 0.89% of the stock is currently owned by insiders.
Illumina, Inc. (NASDAQ:ILMN) opened at $229.20 on Friday. The company has a market cap of $33,692.40, a P/E ratio of 57.16, a P/E/G ratio of 3.03 and a beta of 0.92. Illumina, Inc. has a 12 month low of $158.02 and a 12 month high of $248.97. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.43.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.22. The company had revenue of $778.00 million during the quarter, compared to the consensus estimate of $752.04 million. Illumina had a net margin of 26.56% and a return on equity of 21.71%. Illumina’s revenue for the quarter was up 25.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.85 earnings per share. analysts forecast that Illumina, Inc. will post 4.59 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2018/02/18/illumina-inc-ilmn-holdings-lifted-by-rhumbline-advisers.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.